Overview

Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms

Status:
Terminated
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to determine the clinical safety of RAD1901 and to evaluate whether RAD1901 reduced the frequency and severity of moderate to severe vasomotor symptoms (VMS; "hot flashes") in postmenopausal women.
Phase:
Phase 2
Details
Lead Sponsor:
Radius Health, Inc.
Radius Pharmaceuticals, Inc.